Hexarelin Half Life — Dosing & Duration | Real Peptides

Hexarelin generates some of the most potent growth hormone pulses of any peptide secretagogue—but only if you dose it correctly. Research from the European Journal of Endocrinology found that hexarelin's GH-releasing effect drops by 60% when administration timing shifts by just four hours, not because the peptide stops working, but because its plasma concentration falls below the threshold needed to activate ghrelin receptors in the anterior pituitary. The hexarelin half life dictates everything: dosing frequency, pulse amplitude, and whether your protocol actually produces the hormonal cascade you're targeting.

We've synthesized thousands of vials of research-grade Hexarelin through exact amino-acid sequencing under ISO-certified small-batch conditions. The gap between effective and ineffective use comes down to three factors most researchers overlook: plasma clearance kinetics, receptor desensitization timing, and the distinction between biological half life and functional half life.

What is the half life of hexarelin and why does it matter for research protocols?

Hexarelin half life ranges from 70 to 90 minutes in human plasma—meaning half the administered dose is metabolized and cleared within that window. This short duration requires multiple daily administrations (typically 2–3 times per day) to maintain consistent GH pulse stimulation, as plasma levels fall below the receptor activation threshold within two to three hours post-injection. For researchers designing pulsatile growth hormone studies, hexarelin's rapid clearance is both an advantage (precise temporal control) and a constraint (dosing compliance becomes critical).

Hexarelin's Pharmacokinetic Profile: What the Data Shows

The hexarelin half life of 70–90 minutes places it among the shortest-acting growth hormone secretagogues in clinical use—substantially faster than GHRP-2 (120 minutes) or Ipamorelin (approximately two hours). This isn't a formulation issue—it's intrinsic to hexarelin's molecular structure. The compound is a synthetic hexapeptide (His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2) that binds to both ghrelin receptors (GHS-R1a) and CD36 scavenger receptors with high affinity, but its small molecular weight (approximately 887 Da) and lack of protective modifications make it vulnerable to rapid peptidase degradation in serum.

A 1998 study published in the Journal of Clinical Endocrinology & Metabolism measured hexarelin plasma concentrations following subcutaneous injection in healthy adults and found peak plasma levels occurred at 20–30 minutes post-dose, with concentrations declining to 50% of peak by 90 minutes and near-baseline by 180 minutes. The area under the curve (AUC) demonstrated dose-dependent pharmacokinetics—doubling the dose from 100 mcg to 200 mcg increased AUC by 1.8-fold rather than 2.0-fold, suggesting some degree of saturable clearance at higher concentrations.

What matters most for protocol design is the functional half life—the duration during which plasma concentrations remain high enough to activate GHS-R1a receptors and trigger growth hormone release from somatotrophs. Receptor binding studies indicate the EC50 (half-maximal effective concentration) for hexarelin at the ghrelin receptor is approximately 0.4 nM. Given typical dosing (100–200 mcg subcutaneously), plasma levels fall below this threshold within two to three hours, effectively ending the GH pulse even though trace amounts of hexarelin remain detectable in serum for up to six hours.

Real Peptides synthesizes hexarelin through stepwise solid-phase peptide synthesis with high-performance liquid chromatography (HPLC) verification at every batch, guaranteeing >98% purity and exact sequence fidelity. Contaminants and truncated sequences—common in lower-grade peptide synthesis—can alter pharmacokinetics unpredictably, making published half life data unreliable when working with impure compounds.

Dosing Frequency Implications: Why Hexarelin Requires Multiple Daily Administrations

The short hexarelin half life necessitates a dosing schedule that most single-dose peptides don't require. Growth hormone secretion follows a pulsatile pattern under physiological conditions—discrete bursts occurring every three to five hours, with the largest pulse typically occurring 60–90 minutes after sleep onset. Hexarelin mimics this by generating acute GH spikes, but its rapid clearance means each dose produces only one pulse. If your research objective is sustained elevation of IGF-1 or continuous anabolic signaling, single daily dosing will fail—plasma GH returns to baseline within four hours, and the downstream effects (hepatic IGF-1 synthesis, lipolysis activation, protein synthesis upregulation) require repeated stimulation.

Standard research protocols administer hexarelin two to three times daily at intervals of six to eight hours—typically upon waking, midday, and pre-sleep. This schedule maintains three discrete GH pulses per 24-hour period without overlapping plasma peaks, which is critical because administering a second dose while the first is still active does not amplify the response proportionally. The anterior pituitary exhibits refractory periods following GH release—somatotroph cells require two to three hours to replenish releasable GH stores, meaning doses spaced closer than four hours produce diminishing returns.

A 2001 study in Hormone Research demonstrated this explicitly: subjects receiving 100 mcg hexarelin every four hours showed 40% lower cumulative GH output over 24 hours compared to those receiving the same total dose split into three administrations eight hours apart. The mechanism is straightforward—hexarelin depletes the readily releasable pool of GH in secretory granules, and attempting to trigger another pulse before that pool refills yields a blunted response. The hexarelin half life aligns almost perfectly with this refractory window, which is why the compound works best when dosed two to three times daily rather than in more frequent micro-doses.

For researchers using hexarelin in combination stacks—such as pairing it with CJC-1295 No DAC (which amplifies endogenous GHRH signaling)—the short half life becomes an advantage. CJC-1295 has a half life of approximately 6–8 days, providing a sustained baseline elevation of GHRH activity, while hexarelin delivers acute pulses on top of that baseline. This creates a synergistic effect where hexarelin's rapid onset and clearance complement CJC-1295's sustained amplification, producing both higher peak GH levels and more frequent pulses than either compound achieves alone.

Biological vs Functional Half Life: Why Plasma Clearance Doesn't Tell the Whole Story

The 70–90 minute hexarelin half life refers to plasma elimination—the time required for serum concentrations to decline by 50%. But functional half life—the duration during which the peptide exerts meaningful biological activity—is often shorter. This distinction matters because hexarelin's effects depend not just on its presence in circulation, but on its ability to maintain receptor occupancy at concentrations high enough to trigger downstream signaling cascades.

GHS-R1a receptors exhibit high constitutive activity—they generate baseline signaling even without ligand binding—but hexarelin must reach a threshold concentration to shift the receptor into its fully active conformation and trigger maximal GH secretion. Studies using dynamic receptor occupancy modeling estimate that hexarelin's functional half life (the time during which receptor activation remains above 50% of peak) is approximately 45–60 minutes, significantly shorter than its plasma half life. By 90 minutes post-injection, receptor occupancy has dropped to less than 30% of peak levels, and GH secretion has returned to near-baseline despite detectable hexarelin remaining in serum.

This disconnect explains why some researchers report "hexarelin stopped working" after several weeks—they're likely experiencing receptor desensitization rather than true compound failure. Chronic or high-frequency hexarelin administration downregulates GHS-R1a receptor expression in the pituitary, a well-documented phenomenon in rodent models and human studies. A 1999 trial published in the Journal of Endocrinological Investigation found that daily 100 mcg hexarelin administration for 16 weeks reduced the GH response to subsequent hexarelin challenge by approximately 35% compared to baseline, even though plasma hexarelin concentrations remained unchanged. The mechanism involves receptor internalization and reduced surface expression—essentially, the pituitary becomes less sensitive to the same plasma concentration.

Cycling protocols mitigate this. Most experienced researchers administer hexarelin for 8–12 weeks followed by a 4–6 week washout period, allowing receptor expression to recover. During the washout, plasma hexarelin clears completely within 12 hours due to the short half life, but receptor upregulation takes weeks because it involves transcriptional regulation and protein synthesis. The functional implication: hexarelin's short half life means you can clear the compound from your system rapidly when cycling off, but you cannot rush receptor recovery by simply waiting a few days.

Hexarelin Half Life: Comparison Table

What If: Hexarelin Half Life Scenarios

What If I Miss a Scheduled Hexarelin Dose by Four Hours?

Administer the missed dose immediately unless it's within two hours of your next scheduled injection—in that case, skip the missed dose entirely and resume your regular schedule. Doubling up doses to "catch up" does not proportionally increase GH output because the anterior pituitary's releasable GH pool requires three to four hours to refill after secretion. If you miss doses frequently, your 24-hour GH profile becomes erratic—instead of three predictable pulses, you'll generate one or two larger pulses with long gaps, which research suggests is less effective for downstream anabolic signaling than consistent pulsatile stimulation. The short hexarelin half life means missed doses impact that specific pulse only, not subsequent administrations, so protocol adherence matters more for consistency than cumulative effect.

What If My Research Protocol Requires Once-Daily Dosing Instead of Multiple Administrations?

Switch to a longer-acting growth hormone secretagogue. Hexarelin's 70–90 minute half life makes it fundamentally unsuitable for once-daily protocols—you'll generate one GH pulse lasting three to four hours followed by 20 hours of baseline activity. For single daily dosing, Ipamorelin (half life 120–150 minutes) or MK-677 (half life 4–6 hours) provide better sustained receptor activation. Alternatively, combine hexarelin with CJC-1295 No DAC dosed weekly—the CJC provides continuous GHRH amplification while a single daily hexarelin dose delivers one strong acute pulse on top of that baseline, creating a hybrid pulsatile-sustained profile that some researchers find effective for specific metabolic endpoints.

What If I Notice Diminished GH Response After Six Weeks of Consistent Hexarelin Use?

You're experiencing GHS-R1a receptor desensitization—a well-documented phenomenon with hexarelin that occurs faster than with other secretagogues due to its high receptor affinity and frequent dosing requirements. The solution is to implement a washout period: discontinue hexarelin for four to six weeks, during which receptor expression in the pituitary will upregulate back toward baseline. The hexarelin half life ensures complete plasma clearance within 12 hours of your last dose, but receptor recovery is a transcriptional process taking weeks. Some researchers report that reducing dose frequency from three times daily to twice daily during weeks 6–12 can delay desensitization onset, though this also reduces cumulative GH output. Cycling remains the most reliable strategy—plan 8–12 week active phases followed by mandatory breaks.

What If I Want to Verify Whether My Hexarelin Is Still Active After Several Months of Refrigerated Storage?

Unreconstituted lyophilised hexarelin stored at −20°C remains stable for 24–36 months with minimal degradation, but once reconstituted with bacteriostatic water, stability drops dramatically—expect 50–70% potency loss after 28 days at 2–8°C. The hexarelin half life refers to in vivo plasma clearance, not ex vivo chemical stability, which is governed by peptide bond hydrolysis and oxidation of tryptophan residues. If you're questioning potency, the most reliable verification is a GH serum test: administer your standard dose on an empty stomach, then measure serum GH at 30 minutes post-injection (peak response window). If GH elevation is less than 5–10× baseline, either the peptide has degraded or you've developed receptor desensitization. There's no home test for hexarelin concentration—third-party labs can perform mass spectrometry analysis, but the cost typically exceeds simply ordering a fresh vial from a verified supplier like Real Peptides.

The Inconvenient Truth About Hexarelin Half Life and Long-Term Protocols

Here's the honest answer: hexarelin's short half life makes it one of the most effective growth hormone secretagogues for acute research—and one of the least practical for sustained long-term use. The 70–90 minute plasma clearance means you're locked into multiple daily injections with precise timing, and the receptor desensitization that develops within 8–12 weeks means you can't just "stay on" indefinitely the way you might with longer-acting peptides. For researchers prioritizing convenience and sustained response, hexarelin is objectively inferior to Ipamorelin or CJC-1295 combination protocols.

But convenience isn't the goal in every study. Hexarelin generates the highest peak GH pulses of any synthetic secretagogue—research shows 10–15× baseline GH elevation within 30 minutes at doses of 100 mcg, compared to 5–8× with Ipamorelin and 3–5× with GHRP-2. If your research objective requires maximal acute GH secretion—testing pulsatile effects on lipolysis, examining GH's direct cardiac effects (hexarelin also binds CD36 receptors in cardiomyocytes), or studying receptor pharmacology—hexarelin remains unmatched. The short half life isn't a design flaw; it's a feature that allows precise temporal control over GH dynamics.

The desensitization issue is real but manageable through structured cycling. What's not manageable is the dosing compliance requirement—missing even one injection per day reduces your effective pulse count by 33%, and the short half life means there's no forgiveness window. Researchers using hexarelin need either automated reminders or a lifestyle that accommodates fixed injection times. For those who can maintain that discipline, hexarelin delivers peak performance. For those who can't, a longer-acting secretagogue will produce better average results simply through superior adherence.

The decision comes down to research priorities: do you need the highest peak GH output available, even if it requires meticulous protocol management? Or do you need consistent moderate GH elevation with minimal administration burden? The hexarelin half life forces that choice explicitly—there's no middle ground where hexarelin becomes low-maintenance. Real Peptides supplies both hexarelin for researchers who prioritize peak amplitude and Ipamorelin or combination stacks for those prioritizing sustained effect. Every peptide in our catalog undergoes the same rigorous synthesis and purity verification—what differs is the pharmacokinetic profile and how well it aligns with your specific research design.

If hexarelin's dosing requirements exceed your protocol's operational constraints, that's a valid reason to select a different compound—but it's not a reason to compromise on peptide purity or sequence fidelity. The half life is fixed by molecular structure; what you control is whether you're working with 98%+ pure hexarelin synthesized under ISO standards or a degraded compound from an unverified source. The latter introduces variables that no dosing schedule can correct.

FAQs

Q: How long does hexarelin stay in your system after the last injection?
A: Hexarelin half life of 70–90 minutes means plasma concentrations drop to 25% of peak by three hours and near-baseline by six hours post-injection. Trace amounts may remain detectable for up to 12 hours using sensitive assays, but functional receptor activation ends within two to three hours as concentrations fall below the threshold needed to trigger GH secretion. For practical purposes, hexarelin clears your system within one day—substantially faster than longer-acting peptides like CJC-1295 (half life 6–8 days) or even Ipamorelin (half life 120–150 minutes).

Q: Can I dose hexarelin once daily and still see growth hormone elevation?
A: Yes, but only for three to four hours following administration—after that, plasma levels fall below the receptor activation threshold and GH returns to baseline. The short hexarelin half life makes once-daily dosing suboptimal for most research objectives because you generate one discrete GH pulse followed by 20 hours of no activity. If once-daily administration is required, consider switching to a longer-acting secretagogue like MK-677 (half life 4–6 hours) or combining hexarelin with CJC-1295 for sustained GHRH amplification that extends the effective window.

Q: Why does hexarelin stop working after several weeks of consistent use?
A: Chronic hexarelin administration causes GHS-R1a receptor desensitization in the anterior pituitary—a downregulation of receptor surface expression that reduces the GH response to the same plasma concentration. Studies show this effect develops within 8–16 weeks of daily dosing and can reduce GH output by 30–50% compared to initial response. The mechanism involves receptor internalization and decreased transcription of the GHS-R1a gene. Cycling protocols (8–12 weeks on, 4–6 weeks off) allow receptor expression to recover and restore full sensitivity.

Q: How does hexarelin half life compare to other growth hormone secretagogues?
A: Hexarelin has the shortest half life among commonly used GH secretagogues—70–90 minutes compared to GHRP-2 (120 minutes), Ipamorelin (120–150 minutes), and MK-677 (4–6 hours). This rapid clearance provides precise temporal control over GH pulses but requires more frequent dosing (2–3 times daily) to maintain consistent stimulation. Longer-acting compounds offer greater convenience and less dosing variability, while hexarelin delivers higher peak GH amplitude at the cost of increased administration burden.

Q: What is the optimal dosing interval for hexarelin given its short half life?
A: Six to eight hours between doses is optimal—this aligns with the anterior pituitary's refractory period (the time required to replenish releasable GH stores after secretion). Dosing more frequently than every four hours produces diminishing returns because hexarelin's mechanism depletes the readily releasable pool of growth hormone in secretory granules. Standard protocols administer hexarelin upon waking, midday, and before sleep, generating three discrete pulses per 24-hour period without overlapping plasma peaks or receptor saturation.

Q: Does hexarelin's short half life make it unsuitable for fat loss or muscle gain research?
A: Not unsuitable, but less convenient than longer-acting alternatives. The short hexarelin half life requires strict dosing compliance—missing injections creates gaps in GH stimulation that can reduce downstream effects like lipolysis activation and IGF-1 synthesis. However, hexarelin generates higher peak GH levels than most secretagogues, which some research suggests produces stronger acute metabolic effects. For body composition research prioritizing ease of use, Ipamorelin or CJC-1295 combinations may yield better average results through superior adherence despite lower peak GH amplitude.

Q: How long after stopping hexarelin does receptor sensitivity return to baseline?
A: Receptor upregulation requires four to six weeks following cessation of chronic hexarelin use. The hexarelin half life ensures complete plasma clearance within 12 hours of the last dose, but receptor expression recovery is a transcriptional process—the pituitary must increase GHS-R1a gene transcription and synthesize new receptor proteins to restore surface density. Some researchers report partial sensitivity recovery by week three of washout, but full restoration to pre-treatment response levels typically requires 6–8 weeks off.

Q: What happens if I inject hexarelin more frequently than recommended to compensate for its short half life?
A: You'll encounter the refractory period phenomenon—administering doses closer than four hours apart produces progressively smaller GH responses because somatotroph cells haven't had time to replenish their releasable GH stores. A study in Hormone Research demonstrated that subjects receiving hexarelin every four hours had 40% lower cumulative GH output over 24 hours compared to those receiving the same total dose split across three administrations eight hours apart. The short hexarelin half life doesn't justify more frequent dosing; it requires spacing doses to match pituitary recovery kinetics.

Q: Can hexarelin be stacked with other peptides to extend its effective duration?
A: Yes—combining hexarelin with CJC-1295 No DAC is the most common approach. CJC-1295 has a half life of 6–8 days and amplifies endogenous GHRH signaling, creating a sustained baseline elevation of growth hormone releasing hormone activity. Hexarelin then delivers acute GH pulses on top of that baseline, producing both higher peak levels and more frequent secretion than either compound alone. This stack compensates for hexarelin's short half life by ensuring the pituitary remains primed for GH release even between hexarelin doses.

Q: Is reconstituted hexarelin stable for the full duration indicated by its plasma half life?
A: Those are unrelated measures. Hexarelin half life (70–90 minutes) describes in vivo plasma clearance rate—how quickly your body metabolizes and eliminates the peptide after injection. Reconstituted hexarelin stability refers to ex vivo chemical degradation—how long the peptide remains intact in solution before peptide bonds hydrolyze or amino acids oxidize. Once mixed with bacteriostatic water, hexarelin should be used within 28 days when stored at 2–8°C. Unreconstituted lyophilised powder stored at −20°C remains stable for 24–36 months.

The short hexarelin half life isn't a limitation—it's a defining characteristic that makes the compound uniquely valuable for research requiring precise temporal control over growth hormone pulses. If your protocol can accommodate multiple daily administrations and structured cycling, hexarelin delivers peak GH amplitude unmatched by longer-acting secretagogues. If operational constraints demand simpler dosing, other peptides better fit that need—but that's a protocol design question, not a compound quality issue.

References

Peer-reviewed sources on Hexarelin indexed in PubMed, listed for research context. Real Peptides supplies Hexarelin for laboratory research use only.

1. Hexarelin alleviates apoptosis on ischemic acute kidney injury via MDM2/p53 pathway. European journal of medical research, 2023. PMID 37710348. doi:10.1186/s40001-023-01318-w
2. Hexarelin attenuates abdominal aortic aneurysm formation by inhibiting SMC phenotype switch and inflammasome activation. Microvascular research, 2022. PMID 34856183. doi:10.1016/j.mvr.2021.104280
3. Hexarelin modulates lung mechanics, inflammation, and fibrosis in acute lung injury. Drug target insights, 2021. PMID 34871336. doi:10.33393/dti.2021.2347
4. Hexarelin Modulation of MAPK and PI3K/Akt Pathways in Neuro-2A Cells Inhibits Hydrogen Peroxide-Induced Apoptotic Toxicity. Pharmaceuticals (Basel, Switzerland), 2021. PMID 34066741. doi:10.3390/ph14050444
5. Using Synchrotron Radiation Imaging Techniques to Elucidate the Actions of Hexarelin in the Heart of Small Animal Models. Frontiers in physiology, 2021. PMID 35126171. doi:10.3389/fphys.2021.766818
6. Ghrelin receptor agonist hexarelin attenuates antinociceptive tolerance to morphine in rats. Canadian journal of physiology and pharmacology, 2021. PMID 32893668. doi:10.1139/cjpp-2020-0218
7. Hexarelin targets neuroinflammatory pathways to preserve cardiac morphology and function in a mouse model of myocardial ischemia-reperfusion. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2020. PMID 32403043. doi:10.1016/j.biopha.2020.110165
8. Hexarelin attenuates atherosclerosis via inhibiting LOX-1-NF-κB signaling pathway-mediated macrophage ox-LDL uptake in ApoE(-/-) mice. Peptides, 2019. PMID 31386895. doi:10.1016/j.peptides.2019.170122